secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2022-05-24T23:59:59+00:00
Accession:  0001493152-22-014942
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo appoints Kenneth Cundy as CSO; $350K salary, options, milestone vesting
-------------------------------------------------------------------------------

- Dr. Cundy appointed CSO effective May 20, 2022; base salary $350,000, annual bonus up to 30%.
- Receives option for 233,446 shares vesting quarterly over 4 years.
- Additional option for 116,273 shares vests upon FDA approval of lead candidate ANEB-001.
- Severance: 9 months' base salary plus COBRA for up to 12 months if terminated without cause.
- Cundy previously CSO at CohBar and XenoPort; coinventor of tenofovir and Nanocrystal technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222014942/0001493152-22-014942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222014942/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-014942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer